By Simon Druker
July 10 (UPI) — The European Union agency responsible for supervising the medical and pharmaceutical sectors is looking into claims of suicidal thoughts experienced by patients of several medications used for weight loss.
The European Medicines Agency confirmed its Pharmacovigilance Risk Assessment Committee is looking at popular drugs containing semaglutide, sold under several brand names including Ozempic and Wegovy.
The review came after concerns were raised during the latest PRAC meeting, following three cases reported by the Icelandic Medicines Agency.
Two of those cases involved suicidal thoughts, while a third person had thoughts of self-injury.
Read the rest of the article here
or as a PDF